Timothy R. O’Connor

Dr. Timothy R. O’Connor


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
CCCaroline C. Clark
Caroline C. Clark
JWJeffrey N. Weitzel
Jeffrey N. Weitzel
TOTimothy R. O’Connor
Timothy R. O’Connor
Individuals with an inherited BRCA1 or BRCA2 mutation have an elevated risk of developing breast cancer. The resulting tumors typically lack homologous recombination repair as do a subset of sporadic tumors with acquired BRCA deficiency. Clinical responses to monotherapy with platinum drugs or poly PARP inhibitors (PARPi) have been shown for BRCA-associated cancers. However, there are limited data on combination therapy with PARPi and platinum drugs, the mechanism of action of this combination, and the role of BRCA1 or BRCA2 in chemosensitivity. We compared the efficacy of ABT-888 (a PARPi) with that of cisplatin or carboplatin (platinum drugs) alone or in combinations by examining the survival of treated Brca-proficient and -deficient mouse embryonic stem cells. In addition, drug-induced growth inhibition of a BRCA1 and a BRCA2 null cell line were compared with their isogenic BRCA-complemented lines. Although each monotherapy killed or inhibited proliferation of Brca/BRCA-deficient cells, an enhanced effect was observed after treatment with ABT-888 in combination with carboplatin. Moreover, the ABT-888/carboplatin combination delayed tumor growth in Brca2 xenografts. The drugs caused DNA damage and apoptosis. Along with greater PARP activity in Brca/BRCA-deficient cells, these effects correlated with increased chemosensitivity. Our data suggest that ABT-888 and carboplatin combination treatment will be more successful than monotherapy in addressing many BRCA-associated cancers. A randomized phase II trial has recently been initiated to test this hypothesis to assist in the discovery of more effective therapies for patients with BRCA. Mol Cancer Ther; 11(9); 1948–58. ©2012 AACR.

6 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLi Z. Luo
Li Z. Luo
SGSailesh Gopalakrishna-Pillai
Sailesh Gopalakrishna-Pillai
SNStephanie L. Nay
Stephanie L. Nay
SPSang-Won Park
Sang-Won Park
SBSteven E. Bates
Steven E. Bates
TOTimothy R. O’Connor
Timothy R. O’Connor
The potential for human disease treatment using human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells (iPSCs), also carries the risk of added genomic instability. Genomic instability is most often linked to DNA repair deficiencies, which indicates that screening/characterization of possible repair deficiencies in pluripotent human stem cells should be a necessary step prior to their clinical and research use. In this study, a comparison of DNA repair pathways in pluripotent cells, as compared to those in non-pluripotent cells, demonstrated that DNA repair capacities of pluripotent cell lines were more heterogeneous than those of differentiated lines examined and were generally greater. Although pluripotent cells had high DNA repair capacities for nucleotide excision repair, we show that ultraviolet radiation at low fluxes induced an apoptotic response in these cells, while differentiated cells lacked response to this stimulus, and note that pluripotent cells had a similar apoptotic response to alkylating agent damage. This sensitivity of pluripotent cells to damage is notable since viable pluripotent cells exhibit less ultraviolet light-induced DNA damage than do differentiated cells that receive the same flux. In addition, the importance of screening pluripotent cells for DNA repair defects was highlighted by an iPSC line that demonstrated a normal spectral karyotype, but showed both microsatellite instability and reduced DNA repair capacities in three out of four DNA repair pathways examined. Together, these results demonstrate a need to evaluate DNA repair capacities in pluripotent cell lines, in order to characterize their genomic stability, prior to their pre-clinical and clinical use.

1 May 2012 in DNA Repair
Verified
Journal Article
Closed access
SNStephanie L. Nay
Stephanie L. Nay
DLDong-Hyun Lee
Dong-Hyun Lee
SBSteven E. Bates
Steven E. Bates
TOTimothy R. O’Connor
Timothy R. O’Connor

24 November 2009 in Biochemistry and Molecular Biology Education
Verified
Journal Article
Open access
PDF file
TOTimothy R. O’Connor
Timothy R. O’Connor
GHGerald P. Holmquist
Gerald P. Holmquist
We present an algorithm for the construction of a strong initial draft. It is designed to overcome writer's block and to assist scientists who are not native English speakers. The writing starts with making figures and tables. These suggest several terse summary statements, the few major conclusions or observations the author will present to the scientific community. After identification of the audience, the specific community addressed, materials and methods are written to explain how the tables and figures were generated. Results are initially restricted to describing the logical data relations in each table and figure. The discussion then converts each data relationship into mechanistic cause‐and‐effect interpretations suitable for the A brief epilogue deals with the submission and the fate of the final manuscript once submitted. Although other models for the initial draft exist, this model has worked for us and new researchers in our laboratories and addresses problems we encountered while editing manuscripts.

1 January 2021 in Cancer Drug Resistance
Verified
Journal Article
Open access
PDF file
RGRoberto Gutierrez
Roberto Gutierrez
TOTimothy R. O’Connor
Timothy R. O’Connor
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.

15 June 2007 in Analytical Biochemistry
Verified
Journal Article
Closed access
HLHyun-Wook Lee
Hyun-Wook Lee
HLHae-Jung Lee
Hae-Jung Lee
CHChong-Mu Hong
Chong-Mu Hong
DBDavid J. Baker
David J. Baker
RBRavi Bhatia
Ravi Bhatia
TOTimothy R. O’Connor
Timothy R. O’Connor